Research programme: MOR 102 antibodies - MorphoSys

Drug Profile

Research programme: MOR 102 antibodies - MorphoSys

Alternative Names: IgG4 antibody - Morphosys; MOR 102 antibodies; MOR 102 antibodies research programme - MorphoSys; MOR102

Latest Information Update: 16 Mar 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 24 Feb 2006 Discontinued - Preclinical for Psoriasis in Germany (unspecified route)
  • 09 Apr 2005 This programme is still in active development
  • 14 Oct 2003 Preclinical data from a media release have been added to the Skin Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top